Podium to Practice: Chicago 2026 – BREAST: OPTIMA
OR
Studies / Trials Discussed
500 – First results from the OPTIMA phase III randomized non-inferiority trial of test-directed chemotherapy in patients with high clinical risk ER-positive HER2-negative early breast cancer.
Explore more from your favourite experts – click their name to access their entire library of content.
Studies/trials discussed:
500 – First results from the OPTIMA phase III randomized non-inferiority trial of test-directed chemotherapy in patients with high clinical risk ER-positive HER2-negative early breast cancer.
Login to view content
PLease Enter Your Email to view Content
Pre-Video Survey
By continuing to watch the video, you consent to receiving a post-view survey by email.